Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria

Howard J. Heller, Alfredo A. Reza-Albarrán, Neil A. Breslau, Charles Y C Pak

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: We tested whether UroPhos section-K, a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily would produce a sustained hypocalciuric response and maintain bone mass in patients with absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss. Materials and Methods: A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily. Results: Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional 47calcium absorption decreased modestly (74.0 to 64.6%) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the normal range (30 to 42 pg./ml.). Bone mineral density was stable at the lumbar spine, femoral neck and distal third of the radius. Conclusions: UroPhos-K may provide a long-term alternative for hypercalciuric patients in whom thiazide therapy fails.

Original languageEnglish (US)
Pages (from-to)1451-1456
Number of pages6
JournalJournal of Urology
Volume159
Issue number5
StatePublished - May 1998

Fingerprint

Hypercalciuria
Calcium
Tablets
Phosphates
Thiazides
Bone and Bones
Nephrolithiasis
Femur Neck
Intestinal Absorption
Therapeutics
Parathyroid Hormone
Bone Density
Inpatients
Potassium
Reference Values
Spine
Sodium
Diet
potassium phosphate
Serum

Keywords

  • Bone density
  • Calcium
  • Delayed-action preparations
  • Phosphates
  • Urinary calculi

ASJC Scopus subject areas

  • Urology

Cite this

Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. / Heller, Howard J.; Reza-Albarrán, Alfredo A.; Breslau, Neil A.; Pak, Charles Y C.

In: Journal of Urology, Vol. 159, No. 5, 05.1998, p. 1451-1456.

Research output: Contribution to journalArticle

@article{98ba8a0ff9a74c2185f1a49b4e9e75d7,
title = "Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria",
abstract = "Purpose: We tested whether UroPhos section-K, a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily would produce a sustained hypocalciuric response and maintain bone mass in patients with absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss. Materials and Methods: A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily. Results: Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional 47calcium absorption decreased modestly (74.0 to 64.6{\%}) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the normal range (30 to 42 pg./ml.). Bone mineral density was stable at the lumbar spine, femoral neck and distal third of the radius. Conclusions: UroPhos-K may provide a long-term alternative for hypercalciuric patients in whom thiazide therapy fails.",
keywords = "Bone density, Calcium, Delayed-action preparations, Phosphates, Urinary calculi",
author = "Heller, {Howard J.} and Reza-Albarr{\'a}n, {Alfredo A.} and Breslau, {Neil A.} and Pak, {Charles Y C}",
year = "1998",
month = "5",
language = "English (US)",
volume = "159",
pages = "1451--1456",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria

AU - Heller, Howard J.

AU - Reza-Albarrán, Alfredo A.

AU - Breslau, Neil A.

AU - Pak, Charles Y C

PY - 1998/5

Y1 - 1998/5

N2 - Purpose: We tested whether UroPhos section-K, a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily would produce a sustained hypocalciuric response and maintain bone mass in patients with absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss. Materials and Methods: A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily. Results: Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional 47calcium absorption decreased modestly (74.0 to 64.6%) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the normal range (30 to 42 pg./ml.). Bone mineral density was stable at the lumbar spine, femoral neck and distal third of the radius. Conclusions: UroPhos-K may provide a long-term alternative for hypercalciuric patients in whom thiazide therapy fails.

AB - Purpose: We tested whether UroPhos section-K, a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily would produce a sustained hypocalciuric response and maintain bone mass in patients with absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss. Materials and Methods: A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily. Results: Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional 47calcium absorption decreased modestly (74.0 to 64.6%) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the normal range (30 to 42 pg./ml.). Bone mineral density was stable at the lumbar spine, femoral neck and distal third of the radius. Conclusions: UroPhos-K may provide a long-term alternative for hypercalciuric patients in whom thiazide therapy fails.

KW - Bone density

KW - Calcium

KW - Delayed-action preparations

KW - Phosphates

KW - Urinary calculi

UR - http://www.scopus.com/inward/record.url?scp=0032459366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032459366&partnerID=8YFLogxK

M3 - Article

VL - 159

SP - 1451

EP - 1456

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -